Skip to main content
Fig. 1 | European Journal of Medical Research

Fig. 1

From: Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis

Fig. 1

The levels of SUA and the prevalence of hypouricemia and hyperuricemia in RA patients with different stratification. The SUA levels in all, male, premenopausal and postmenopausal female RA patients A; The prevalence of hypouricemia and hyperuricemia in different gender B and treatment groups C; The prevalence of hyperuricemia in different age D, disease duration E, disease activity groups F; The prevalence of hypouricemia in different age G, disease duration H, disease activity groups I. *P < 0.05; **P < 0.01; ***P < 0.001. â–³Treatment naïve, without previous corticosteroids or disease-modifying anti-rheumatic drugs treatment for 6 months before recruited. RA rheumatoid arthritis; Remission (CDAI ≤ 2.8), LDA low disease activity (2.8 < CDAI ≤ 10), MDA moderate disease activity (10 < CDAI ≤ 22), HAD high disease activity (CDAI > 22)

Back to article page